Literature DB >> 3689660

Cellular heterogeneity in normal and neoplastic human urothelium: a study using murine monoclonal antibodies.

G Dotsikas1, T Konowalchuk, P P Major, P E Kovac, G K Ward, S S Stewart, G B Price, M M Elhilali, W J Mackillop.   

Abstract

To assist in the description of the cellular heterogeneity present in normal and neoplastic urothelium, a panel of monoclonal antibodies (MoAbs) was raised against human transitional cell carcinoma (TCC) of the urinary bladder. All immunizations were carried out using whole cells and membrane preparations from well differentiated human TCCs. Two fusions produced 145 hybridomas. Following primary screening by ELISA and secondary screening with immunohistochemistry, three useful antibodies were identified. MoAb 35.48 binds to all cell layers of the normal urothelium and well differentiated tumours, but not to the majority of poorly differentiated tumours. MoAb 21.48 binds preferentially to the basal cell layer of normal urothelium and to some well differentiated papillary TCCs, but poorly differentiated tumours exhibit diffusely positive staining. MoAb 21.48 also shows cross-reactivity with basal cell layers of other epithelia. MoAb 5.48 binds preferentially to the superficial cell layers of normal urothelium and well differentiated TCCs, but exhibits less binding in poorly differentiated tumours with loss of the preferential superficial staining. Quantitative flow cytometric studies indicate that MoAb 5.48 binds to a cell-surface antigen which is present on significantly fewer cells of poorly differentiated tumours than on either normal urothelium (P less than 0.05), or well differentiated tumours (P = 0.05).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689660      PMCID: PMC2001815          DOI: 10.1038/bjc.1987.220

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Survival following transurethral resection of bladder carcinoma.

Authors:  R W Barnes; A L Dick; H L Hadley; O L Johnston
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

3.  Cellular heterogeneity in normal human urothelium: an analysis of optical properties and lectin binding.

Authors:  G K Ward; S S Stewart; G B Price; W J Mackillop
Journal:  J Histochem Cytochem       Date:  1986-07       Impact factor: 2.479

Review 4.  Surgical management of low stage bladder cancer.

Authors:  W F Whitmore
Journal:  Semin Oncol       Date:  1979-06       Impact factor: 4.929

5.  Mouse myelomas and lymphomas in culture.

Authors:  K Horibata; A W Harris
Journal:  Exp Cell Res       Date:  1970-04       Impact factor: 3.905

6.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

7.  A better cell line for making hybridomas secreting specific antibodies.

Authors:  M Shulman; C D Wilde; G Köhler
Journal:  Nature       Date:  1978-11-16       Impact factor: 49.962

8.  Monoclonal antibodies to antigens abnormally expressed in breast cancer.

Authors:  P P Major; P E Kovac; M L Lavallée; E C Kovalik
Journal:  J Histochem Cytochem       Date:  1987-02       Impact factor: 2.479

9.  Cell surface antigens of human bladder tumors: definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics.

Authors:  Y Fradet; C Cordon-Cardo; W F Whitmore; M R Melamed; L J Old
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

10.  Density/volume analysis in the study of cellular heterogeneity in human ovarian carcinoma.

Authors:  W J Mackillop; S S Stewart; R N Buick
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

View more
  8 in total

Review 1.  Normal and neoplastic urothelial stem cells: getting to the root of the problem.

Authors:  Philip Levy Ho; Antonina Kurtova; Keith Syson Chan
Journal:  Nat Rev Urol       Date:  2012-08-14       Impact factor: 14.432

Review 2.  Cancer stem cells in bladder cancer: a revisited and evolving concept.

Authors:  Keith Syson Chan; Jens-Peter Volkmer; Irving Weissman
Journal:  Curr Opin Urol       Date:  2010-09       Impact factor: 2.309

3.  Cellular heterogeneity in human transitional cell carcinoma: an analysis of optical properties and lectin binding.

Authors:  G K Ward; S S Stewart; G Dotsikas; G B Price; W J Mackillop
Journal:  Histochem J       Date:  1992-09

4.  Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.

Authors:  P J Russell; K Davis; E Kingsley; J Humphreys; J Hanley; H O'Grady; N Pearce
Journal:  Cell Biophys       Date:  1994

5.  Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.

Authors:  P J Russell; J Plomley; I H Shon; H O'Grady; N Pearce
Journal:  Cell Biophys       Date:  1993 Jan-Jun

6.  The development of a malignant tumor is due to a desperate asexual self-cloning process in which cancer stem cells develop the ability to mimic the genetic program of germline cells.

Authors:  Vladimir Vinnitsky
Journal:  Intrinsically Disord Proteins       Date:  2014-07-18

7.  Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors.

Authors:  Margarida Ferreira-Teixeira; Belmiro Parada; Paulo Rodrigues-Santos; Vera Alves; José S Ramalho; Francisco Caramelo; Vitor Sousa; Flávio Reis; Célia M Gomes
Journal:  Oncotarget       Date:  2015-11-03

8.  Relationship between immunohistochemical staining extent of CD47 and histopathologic features of bladder tumor.

Authors:  Erkan Olcucuoglu; Mehmet Emin Sirin; Gulden Aydog; Eymen Gazel; Sedat Tastemur; Oner Odabas
Journal:  Cent European J Urol       Date:  2017-10-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.